SKF-83959 is a synthetic benzazepine derivative that has garnered significant attention in scientific research due to its unique pharmacological profile. It acts as a full agonist at the D1 protomer and a high-affinity partial agonist at the D2 protomer within the D1–D2 dopamine receptor heteromer. This compound also exhibits allosteric modulator properties at the sigma-1 receptor, further distinguishing its activity. SKF-83959 is known to inhibit sodium channels and delayed rectifier potassium channels, adding to its diverse range of effects.
Research has shown that SKF-83959 can influence cognitive functions, making it a subject of interest in studies related to Alzheimer’s disease and depression. It has been observed to reverse scopolamine-induced cognitive impairments in animal models, suggesting potential therapeutic benefits. Additionally, SKF-83959’s ability to modulate the sigma-1 receptor may contribute to its neuroprotective effects.
Despite its promising properties, the use of SKF-83959 is primarily confined to research settings. Its complex pharmacological actions, including its partial agonism at D1 receptors and its effects on various signaling pathways, require careful consideration. Recent studies have challenged the notion that SKF-83959 is a highly-biased functionally selective D1 dopamine receptor ligand, suggesting that its behavioral effects can be attributed to its partial agonism rather than any unique signaling mechanisms.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | SKF-83, 959, SKF 83959 |
|---|---|
| IUPAC Name | 9-chloro-3-methyl-5-(3-methylphenyl)-1, 2, 4, 5-tetrahydro-3-benzazepine-7, 8-diol |
| CAS | 80751-85-5 |
| Molecular Weight | 317.8 |
| Molecular Formula | C18H20ClNO2 |
| SMILES | CC1=CC(=CC=C1)C2CN(CCC3=C(C(=C(C=C23)O)O)Cl)C |